17 December 2018 - 52% difference in price on average between winning bids under centralised bulk drugs procurement pilot and last year’s lowest prices for the same drugs.

Can Chinese generic drug makers remain profitable under Beijing’s new state procurement mechanism that has already led to a fall in average selling prices by more than half?

Yes they can, according to analysts who say tender winners will be able to offset the impact of lower prices through savings made possible by bigger volumes and the elimination of hefty distribution costs under the current, distorted pricing mechanism.

Read South China Morning Post article